These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34145944)

  • 81. [Identification of clinical features and laboratory abnormalities associated with the development of vertebral fractures in women with postmenopausal osteoporosis].
    Cerdà D; Peris P; Monegal A; Albaladejo C; Surís X; Guañabens N
    Med Clin (Barc); 2012 Dec; 139(14):626-30. PubMed ID: 22459575
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy.
    Migliaccio S; Francomano D; Romagnoli E; Marocco C; Fornari R; Resmini G; Buffa A; Di Pietro G; Corvaglia S; Gimigliano F; Moretti A; de Sire A; Malavolta N; Lenzi A; Greco EA; Iolascon G
    J Endocrinol Invest; 2017 Dec; 40(12):1321-1326. PubMed ID: 28589380
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates.
    Miller PD; Pannacciulli N; Malouf-Sierra J; Singer A; Czerwiński E; Bone HG; Wang C; Huang S; Chines A; Lems W; Brown JP
    Osteoporos Int; 2020 Jan; 31(1):181-191. PubMed ID: 31776637
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effects and management of denosumab discontinuation.
    Chapurlat R
    Joint Bone Spine; 2018 Oct; 85(5):515-517. PubMed ID: 29317292
    [No Abstract]   [Full Text] [Related]  

  • 85. Are drug holidays a safe option in treatment of osteoporosis? - Insights from an in silico mechanistic PK-PD model of denosumab treatment of postmenopausal osteoporosis.
    Martínez-Reina J; Calvo-Gallego JL; Pivonka P
    J Mech Behav Biomed Mater; 2021 Jan; 113():104140. PubMed ID: 33080564
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand.
    Pongchaiyakul C; Nanagara R; Songpatanasilp T; Unnanuntana A
    J Med Econ; 2020 Jul; 23(7):776-785. PubMed ID: 32063082
    [No Abstract]   [Full Text] [Related]  

  • 87. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
    Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
    J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Multiple vertebral fractures following discontinuation of denosumab treatment: Ten clinical cases report.
    Fernández Fernández E; Benavent Núñez D; Bonilla Hernán G; Monjo Henry I; García Carazo S; Bernad Pineda M; Balsa Criado A; Aguado Acín P
    Reumatol Clin (Engl Ed); 2020; 16(6):480-484. PubMed ID: 30846260
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk.
    Shrestha Khatri N; Stuckey BG
    Med J Aust; 2022 Apr; 216(6):283-284. PubMed ID: 35267213
    [No Abstract]   [Full Text] [Related]  

  • 90. Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk.
    Goss A
    Med J Aust; 2022 Sep; 217(5):268. PubMed ID: 35948307
    [No Abstract]   [Full Text] [Related]  

  • 91. Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk.
    Stuckey BG; Khatri NS
    Med J Aust; 2022 Sep; 217(5):268. PubMed ID: 35948314
    [No Abstract]   [Full Text] [Related]  

  • 92. Risk factors for denosumab discontinuation in patients with postmenopausal osteoporosis.
    Hattori K; Takahashi N; Kojima T; Imagama S
    Mod Rheumatol; 2023 Jul; 33(4):843-850. PubMed ID: 35788363
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases.
    Dupont J; Appermans W; Dejaeger M; Wauters I; Laurent MR; Gielen E
    Bone Rep; 2022 Jun; 16():101582. PubMed ID: 35585959
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Preventing Rebound-Associated Fractures after Discontinuation of Denosumab Therapy: A Position Statement from the Health Insurance Committee of the Korean Endocrine Society.
    Kim BK; Kim CH; Min YK
    Endocrinol Metab (Seoul); 2021 Aug; 36(4):909-911. PubMed ID: 34474520
    [No Abstract]   [Full Text] [Related]  

  • 95. Bone Health and Denosumab Discontinuation in Oncology Populations.
    Cheung YM; Morgans A; Hamnvik OR
    Oncologist; 2022 Dec; 27(12):998-1003. PubMed ID: 36250799
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Long-Term Treatment of Postmenopausal Osteoporosis.
    Brown JP
    Endocrinol Metab (Seoul); 2021 Jun; 36(3):544-552. PubMed ID: 34154042
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Combined Effects of Exercise and Denosumab Treatment on Local Failure in Post-menopausal Osteoporosis-Insights from Bone Remodelling Simulations Accounting for Mineralisation and Damage.
    Martínez-Reina J; Calvo-Gallego JL; Pivonka P
    Front Bioeng Biotechnol; 2021; 9():635056. PubMed ID: 34150724
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Effects of the different administration frequencies of teriparatide (PTH [1-34]) on new bone formation of expanded midpalatal sutures in rats: A histomorphometric and micro-computed tomography analysis.
    Koca CG; Sadry S; Asker H; Çiçek MF; Kösehasanoğulları M; Kaya G
    Orthod Craniofac Res; 2021 Aug; 24(3):449-457. PubMed ID: 34169642
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Denosumab in active Charcot neuro-osteoarthropathy of the foot.
    Carvès S; Bourgeon-Ghittori M; Henry J; Belkhir R; Besson FL; Levante S; Mariette X; Seror R
    Joint Bone Spine; 2021 Dec; 88(6):105241. PubMed ID: 34146697
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence.
    Grassi G; Chiodini I; Palmieri S; Cairoli E; Arosio M; Eller-Vainicher C
    Eur J Endocrinol; 2021 Aug; 185(3):387-396. PubMed ID: 34232124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.